AMGN Insider Sale: SVP & CCO Disposes 1,267 Shares on 08/20/2025

Rhea-AI Filing Summary

Nancy A. Grygiel, SVP & CCO of Amgen Inc. (AMGN), reported a sale of common stock on 08/20/2025. The filing shows 1,267 shares were disposed of at a price of $296.985 per share. After this transaction the reporting person directly beneficially owned 7,209 shares.

The filing also discloses an indirect interest of 103.8077 shares held through Amgen's 401(k) plan. The report notes that 80 dividend equivalents were credited to unvested RSUs and are paid in shares per the company plan.

Positive

• Transparent Section 16 disclosure with transaction date, share amount, and sale price clearly reported
• Dividend equivalents explanation clarifies treatment of 80 DEs on unvested RSUs
• 401(k) holdings disclosed showing indirect beneficial ownership in company stock fund

Negative

• Reduction in direct holdings following disposal of 1,267 shares

Insights

Financial Analyst

TL;DR: Routine insider sale of 1,267 shares at $296.985; changes to direct holdings appear modest versus typical insider ownership.

The reported transaction is a disposition by a named executive officer rather than an acquisition, reducing direct holdings to 7,209 shares. The sale price of $296.985 is explicitly stated and the filing lists an indirect holding of 103.8077 shares in the company 401(k) plan. No derivative transactions, grants, or new option exercises are reported here. This appears to be a standard Section 16 disclosure of an open-market or otherwise reportable sale rather than a material corporate event.

Corporate Governance Expert

TL;DR: Disclosure meets Section 16 reporting requirements; sale includes note on dividend equivalents tied to RSUs.

The Form 4 identifies the reporting person, role (SVP & CCO), and provides transaction specifics including date, number of shares sold, and sale price. The explanation clarifies that 80 dividend equivalents are credited to unvested RSUs and paid in shares per the equity plan. The filing contains no indication of Rule 10b5-1 plan execution or other special selling programs. From a governance and compliance perspective, the form communicates required details for investor transparency.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Grygiel Nancy A.

(Last) (First) (Middle)

ONE AMGEN CENTER DRIVE

(Street)

THOUSAND OAKS CA 91320

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AMGEN INC [ AMGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP & CCO

3. Date of Earliest Transaction (Month/Day/Year)
08/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/20/2025		S		1,267	D	$296.985	7,209(1)	D
Common Stock								103.8077(2)	I	401(k) Plan

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares include 80 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

2. These are shares acquired under the Company's 401(k) Plan and represent interests in the Company's stock fund as of this filing.

	/s/ Nancy A. Grygiel	08/21/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Amgen insider Nancy Grygiel report on Form 4 (AMGN)?

The report discloses a sale of 1,267 shares of Amgen common stock on 08/20/2025 at $296.985 per share.

How many shares does Nancy Grygiel beneficially own after the reported transaction?

Following the reported disposition, she directly beneficially owns 7,209 shares and indirectly holds 103.8077 shares through the 401(k) plan.

Were any dividend equivalents or RSU details disclosed in the Form 4 for AMGN?

Yes. The filing states 80 dividend equivalents were credited to unvested RSUs and are paid out in shares under the equity plan.

Does the Form 4 indicate an option exercise or derivative transaction?

No. The filing shows a non-derivative sale of common stock and does not report any derivative securities or option exercises.

Is there any indication the sale was made under a 10b5-1 plan?

The Form 4 does not indicate that the transaction was made pursuant to a Rule 10b5-1 plan; no such checkbox or statement appears in the provided content.